Europe Artificial Tears Market Research and Forecast 2018-2023

Posted by Orion Market Research on August 3rd, 2018

The Artificial Tears market is growing impressively due to rise in prevalence rate of Kerato Conjunctivitis Sicca, generally known as Dry Eye Syndrome (DES). It is the most often multi-factorial disease of the ocular surface with tears causing discomfort, visual disturbance, and tear film instability with potential damage to the ocular surface. Digital transformation in the recent years, which has enabled all the tasks on diverse platforms such as laptops and smartphones has been a major motivator in the growth of artificial tears market. The prolonged exposure to these device screens is the main factor for increasing rate of ocular diseases. Additionally, significant increase in correctional surgeries and rise in usage of contact lenses have affected the market in a positive manner. The prevalence of dry eye generally increases with age, standing at 9% in patients over the age of 40 and rising to 15% in people aged more than 65. This population is more vulnerable to this disease.

Browse full report at: Europe Artificial Tears Market Research

However, artificial tears solutions hold some side-effects such as red eyes, irritation, vision changes, eye pain and other allergic reactions. This is somehow hindering the market growth. The solution is applicable to short term only, which makes it less suitable for certain applications and the new effective treatments for DES are some restraints that can affect the market growth. Moreover, technological advancements in the new products such as preservative free artificial tears are some market opportunities, which are expected to be widely accepted by individuals during the forecast period.

Related Reports: Healthcare IT

Key companies included in the report are Abbott Medical Optics Inc., Akorn, Inc., Alcon Laboratories, Inc., Allergan, Inc., Bausch and Lomb, Johnson & Johnson, NicOx Inc., Novagali Pharma S.A., Novamedica LLC, Novartis International AG, Ocusoft Inc., Rohto Pharmaceutical Co., Ltd, Santen Pharmaceutical Co. Ltd, Similasan Corp., URSAPHARM Arzeinmittel GmbH, WUHAN Yuanda and so on.  The companies in the artificial tears market are constantly focusing on product launches covering a wide range of users, R&Ds, partnerships, M&As, and technological advancements. The report also includes detailed market overview, strategic recommendations, key company analysis, key findings, analyst insights, predictive analysis, pipeline analysis, market determinants, market segmentation, geographical analysis, and company profiling of the market.